Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver

Trial Profile

Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver

Discontinued
Phase of Trial: Phase 0

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Liver cancer; Uveal melanoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2016 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
    • 28 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top